Joseph M. Alexander
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joseph M. Alexander has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Dietrich von Stechow
Orthopedic Biomechanics Laboratory, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
1 shared publication - Dror Yahalom
Bone and Mineral Metabolism Unit, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
1 shared publication - Itai Bab
The Hebrew University of Jerusalem
1 shared publication - Michael Chorev
Bone and Mineral Metabolism Unit, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
1 shared publication - Ralph Müller
Institute for Biomechanics, ETH Zürich, Zürich, Switzerland
1 shared publication - Susan Fish
Bone and Mineral Metabolism Unit, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
- 28 April 2003
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 4 (1) , 8
Does simvastatin stimulate bone formation in vivo?
- 28 April 2003
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 4 (1) , 8
Open AccessDoes simvastatin stimulate bone formation in vivo?
- 1 July 2001
- Published by Wiley in Brain Pathology
- Vol. 11 (3) , 342-355
Tumor Suppressor Loss in Pituitary Tumors
The current model of human neoplasia invokes a number of potential genomic alterations that impact cellular phenotype and proliferative rates. In the majority of human tumor models, the transformation from normal cells to neoplastic lesion is a multistep process. This review offers a specific overview of the involvement of tumor suppressor genes (TSGs) in the pathogenesis of human pituitary adenomas. TSG genetic lesions, such as BRCA1 in breast cancer and p53 in Li‐Fraumeni Syndrome, have been identified in both sporadic and heritable human endocrine tumors. Familial neoplastic syndromes like multiple endocrine neoplasia type 1 (MEN1) that include pituitary tumor formation as part of a broad clinical spectrum of disease represent a unique opportunity to investigate the general mechanisms of tumorigenesis, and well as genes responsible for sporadic endocrine tumors. Similarly, homologous recombination knockout mice with selectively ablated candidate TSGs have also shed light on the molecular mechanisms of pituitary cell proliferation and tumor suppression. However, despite insights into pituitary tumorigenesis generated by heritable neoplasia syndromes and mouse knockout of critical TSGs that display a pituitary tumor phenotype, the molecular pathogenesis of human pituitary adenomas remains largely an enigma. Thus, the role of TSGs, if any, in sporadic pituitary adenoma formation has yet to be determined, despite our greater understanding of the molecular mechanisms underlying pituitary cell function and phenotype.
- 1 July 2001
- Published by Wiley in Brain Pathology
- Vol. 11 (3) , 342-355
Tumor Suppressor Loss in Pituitary Tumors
The current model of human neoplasia invokes a number of potential genomic alterations that impact cellular phenotype and proliferative rates. In the majority of human tumor models, the transformation from normal cells to neoplastic lesion is a multistep process. This review offers a specific overview of the involvement of tumor suppressor genes (TSGs) in the pathogenesis of human pituitary adenomas. TSG genetic lesions, such as BRCA1 in breast cancer and p53 in Li‐Fraumeni Syndrome, have been identified in both sporadic and heritable human endocrine tumors. Familial neoplastic syndromes like multiple endocrine neoplasia type 1 (MEN1) that include pituitary tumor formation as part of a broad clinical spectrum of disease represent a unique opportunity to investigate the general mechanisms of tumorigenesis, and well as genes responsible for sporadic endocrine tumors. Similarly, homologous recombination knockout mice with selectively ablated candidate TSGs have also shed light on the molecular mechanisms of pituitary cell proliferation and tumor suppression. However, despite insights into pituitary tumorigenesis generated by heritable neoplasia syndromes and mouse knockout of critical TSGs that display a pituitary tumor phenotype, the molecular pathogenesis of human pituitary adenomas remains largely an enigma. Thus, the role of TSGs, if any, in sporadic pituitary adenoma formation has yet to be determined, despite our greater understanding of the molecular mechanisms underlying pituitary cell function and phenotype.